Core growth solid, epitaxy launch delayed by govt approval
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Q2 beat ₹30+ Cr target; epitaxy launch guidance (Nov–Dec) at risk pending govt clearance
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
RIR beat Q2 guidance at ₹34 Cr with 32.5% YoY growth and healthy ₹39 Cr order backlog, validating core business momentum. However, the critical catalyst—SiC epitaxy launch—faces government regulatory delays that could slip into Q4, and commercialization success is unproven. Margin compressed 40 bps YoY to 16.6% due to raw-material cost inflation. Near-term hinges on epitaxy execution; long-term opportunity is real but timing is uncertain.
₹34 Cr
Revenue · +32.5% YoY₹4.4 Cr
Reported PAT · +41.2% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 revenue ₹34 Cr is sustainable recurring base
OVERSTATEDQ1 ₹27.2 Cr, Q2 ₹34 Cr shows growth but order book ₹39 Cr limits runway without epitaxy
32.5% YoY revenue growth vs Q2 FY26
MET₹33.98 Cr vs ₹25.64 Cr = 32.5% YoY confirmed
No one-time items, all routine operating revenue
METManagement stated: These are constantly operating routine revenue, no one-time events
Epitaxy facility to launch Q3 (Nov-Dec) 2026
MISSAlmost done, but waiting govt clearances; management hoping Nov, definitely Dec - timeline at risk
Order backlog improved significantly
METNow ₹39 Cr, was ₹17.4 Cr Mar 31 (2.24x improvement); strong but over-concentration risk
Earnings quality
What changed since the last call
Order backlog surge
Upgrade₹39 Cr vs ₹17.4 Cr on Mar 31 (2.24x); backlog ~115% of quarterly revenue, validates demand
Epitaxy timeline uncertainty
DowngradeGovt clearances delayed; Nov–Dec launch now hoped for, not confirmed (prior: Q3 FY'27 expected)
Margin pressure sustained
DowngradeEBITDA margin 16.6% vs 17% prior year; geopolitical raw-material inflation ongoing
The Q&A
Analysts pressed hard on epitaxy timeline (3 questions), forward guidance (dodged repeatedly), capacity specifics, and ₹100M revenue aspirations. Management held firm on not giving FLS but defended backlog and market position; tone was defensive on govt delays (Mehta: frustrated with clearance pace).
Epitaxy plant timeline — Charchit Maloo, Gemini Capital
DodgedAlmost everything done, waiting govt of Odisha clearances (building, fire clearance in process). No firm timeline; depends on govt approvals.
Forward revenue and EBITDA — Charchit Maloo, Gemini Capital
DodgedWe don't give forward-looking statements. First and second quarter growth shows we're not looking to go back; confident on growth trajectory.
Base-case revenue run-rate — Prateek Giri, Shubh Labh Research
AnsweredAlmost close to ₹30 Cr. Order backlog ₹39 Cr. Shifted problem from market to plant. Working on productivity to grow base. Yes, ₹34 Cr should be base case.
Epitaxy reactor capacity — Keshav, Niveshaay
PartialExpecting ₹12–15 Cr revenue next 4–6 months from epitaxy. Output depends on wafer specs, thickness, coating microns. ~5000 wafers/month possible; productivity varies by spec.
Capacity utilization and backlog — Saurabh Jain, Sequent Investment
AnsweredLPD at ~90% utilization. Equipment no capacity issue, mostly assembly. Order backlog ₹39 Cr as of Q2 end.
FY27–28 revenue guidance — Saurabh Jain, Sequent Investment
DodgedWe don't give forward-looking statements.
BSV HVDC strategic opportunity — Vijendra, Individual investor
AnsweredAlready participating, submitted interest. Ministry & power ministry looking at development plan. Will submit plan in ~1 month.
SiC factory utilization timeline — Vijendra, Individual investor
PartialSet to go for production. Hoping November, definitely December production start. Govt clearances coming through. No detailed utilization forecast given.
Competitive position and scale — Somnath Paul, Relay Investments
AnsweredUnique position as highest value-chain player in India (SiC to systems). Others start from scratch; RIR has 2.5-year head start. Focus on high-value, low-competitive products. Railway/defense/HVDC offer infrastructure tailwinds. SiC epi will be key product differentiator.
Revenue scale aspirations — Somnath Paul, Relay Investments
DodgedManagement vague: aspirations are per the tenders available. Order book will be main driver once Odisha project launches. Ramesh: once Odisha phase completes, numbers will be totally different.
FY29 inflection and growth drivers — Ashish Soni, MM Capital
AnsweredGrowth from all verticals; not leaving anything. Railway 70–80% growth potential. Defense in early stages. Focused on high-value, high-margin products. Will avoid blanket forward guidance but optimistic on future.
Guidance
Q2/3/4 quarterly core business ₹30+ Cr (vs Q1 ₹27.2 Cr)
HighQ2 delivered ₹34 Cr, beating target; ₹39 Cr backlog supports near-term runway
SiC epitaxy ₹12–15 Cr H2 FY'27 (9-month period)
MediumDepends on Nov–Dec plant launch and govt clearances; reaffirmed on call
Sustainable EBITDA margin 15–17% (from Q1 call)
MediumQ2 at 16.6%; raw-material inflation ongoing but within band so far
Epi-wafer margin 20–25% (long-term unproven)
LowNot validated; epitaxy is new product, margins dependent on mix and scale
FY'27 capex ₹100–120 Cr for Odisha Phase 1
MediumPhase 1B (packaging) still awaiting bank approval; Phase 1A (epitaxy) in final approval stage
Risks the call surfaced
Epitaxy regulatory delay
HighOdisha facility awaiting govt building and fire clearances; no firm launch date. Slippage could push production start to Q4 or later, delaying ₹12–15 Cr H2 revenue by 6+ months and forcing guidance miss.
SiC product commercialization
HighSiC epitaxial wafers are new product with no commercial track record. Reactor recently installed; volume production unproven. Customer acceptance, process yields, and cost competitiveness vs global players unvalidated. Loss of design wins or margin compression could derail ₹12–15 Cr H2 plan.
Government policy / order dependency
MediumRailway, defense, and HVDC (BSV) orders are key growth drivers but all government-backed or government-specified. Policy changes, procurement delays, or priority shifts could stall order flow. Railway business is repeat but subject to ministry capex cycles.
Margin compression from raw-material inflation
MediumEBITDA margin fell 40 bps YoY to 16.6% due to 2.8% raw-material cost inflation (geopolitical). If inflation persists or accelerates, margin could fall below 15% target band, pressuring profits even if revenue grows.
Order backlog burn-out without epitaxy
MediumCurrent backlog ₹39 Cr is only ~115% of quarterly revenue. At ₹34 Cr/quarter run-rate, backlog depletes in ~4–5 quarters without new orders. Core business (LPD, HPD, Equipment) has limited growth headroom; new orders depend on railway/defense/HVDC tenders. If epitaxy launch slips and new orders don't materialize, Q4–Q1 FY'28 could see revenue stall or decline.
Large capex burden on balance sheet
MediumFY'27 capex target ₹100–120 Cr is very large vs quarterly profit of ₹4.4 Cr (~6 quarters of profit). Phase 1B (packaging) awaiting bank loan approval. If funding is delayed, equity dilution or debt/leverage could increase. Loss of government subsidy (₹5% interest subsidy) would worsen economics.
Management
Score 6/10. Decent clarity on operations and product roadmap; evasive on forward guidance (repeatedly declined to give FY27–28 targets despite analyst pressure). Transparent on backlog and order book. Q2 beat Q1 guidance (₹34 Cr vs ₹30+ Cr target); epitaxy delay is first significant miss on timeline. Operating leverage intact; margins held within band despite inflation.
1 · Q3 FY27 (Nov–Dec)
Epitaxy plant launch pending Odisha govt regulatory clearances; critical for H2 ₹12–15 Cr target
2 · Q3–Q4 FY27
Railway repeat orders and first defense trial orders expected; 70–80% growth potential
3 · H2 FY27
SiC epitaxy product validation with international and domestic customers; de-risks long-term TAM
Near-term hinges on epitaxy execution; long-term opportunity is real but timing is uncertain.
RIR Power Q2 PAT up 41% YoY to ₹4.45 Cr; OPM slips to 13.6%, below 15-17% guidance
PAT +41.2% YoY · revenue +32.51% · margins compressing
₹33.98 Cr
+32.51% YoY
₹4.45 Cr
+41.2% YoY
12.5%
-3.6pp YoY
₹0.56
RIR Power Electronics posted standalone revenue of ₹33.98 Cr for Q2 FY27, up 32.5% YoY and 25.1% QoQ, comfortably clearing the ₹30+ Cr quarterly target management set out on the Q1 FY27 call. Standalone PAT came in at ₹4.45 Cr, up 41.2% YoY and 41.7% QoQ, with basic EPS at ₹0.56 versus ₹0.47 a year ago. This is a standalone-only filer — RIR has no consolidated statement in this or prior filings, so standalone is the only basis available.
Q2 FY-2027 vs prior quarters
The bottom-line growth masks a core-margin miss. Operating margin (EBITDA/revenue) compressed to 13.62% from 17.01% a year ago and 14.66% last quarter — a third straight quarter of decline, and below management's own 15-17% "sustainable EBITDA margin" guidance from the Q1 call. Net margin held essentially flat YoY (12.50% vs 11.97%) only because other income more than doubled to ₹1.61 Cr (from ₹0.66 Cr) — likely interest income on the ₹9.24 Cr government grant and higher bank balances received this half — and the effective tax rate fell to ~19.7% from ~27.7% a year ago. Strip those two tailwinds out and the underlying operating print is weaker than the headline PAT growth suggests.
The stock went into the print at ₹148.85, down 21.8% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
Core business targeting ₹30+ Cr quarterly (vs current ₹27.2 Cr, implying ~10% growth). Odisha epitaxy production Q3 FY'27; revenue ₹12-15 Cr H2 FY'27. Sustainable EBITDA margin target 15-17%. Epi wafer margin 20-25%. FY'27 capex ₹100-120 Cr for Phase 1.
— This quarter: missed
No formal street estimates for this quarter turned up in search, so vs-street is unknown — RIR is a small-cap with no visible brokerage coverage. On guidance, the company beat its own revenue target but missed its own margin target, a mixed scorecard. The September SiC wafer reactor installation at the Odisha unit ties to the capex buildout: H1 FY27 capex on PP&E ran ~₹35.5 Cr per the cash flow statement, and capital work-in-progress rose to ₹79.75 Cr from ₹46.88 Cr at FY26-end, tracking toward the ₹100-120 Cr FY27 Phase-1 capex management guided. No management press release/commentary was available with this filing to cross-check against the numbers.
W1
Odisha epitaxy production start in Q3 FY27 and the guided ₹12-15 Cr H2 FY27 incremental revenue — unconfirmed this quarter
W2
OPM trajectory: three straight quarters of decline (17.0% → 14.7% → 13.6%) against management's 15-17% guided band
W3
FY27 capex pace: ~₹35.5 Cr spent in H1 against ₹100-120 Cr full-year Phase-1 guidance — H2 run-rate to watch
Standalone-only filer (no consolidated statement in this or prior filings); figures converted from ₹ Lakhs; tax = current tax ₹1.2291 Cr + deferred tax ₹(0.1374) Cr, no prior-period tax; no extraordinary items. Context's year-ago comparison figure was tagged 'consolidated' (PAT ₹4.23 Cr, NPM 16.1%) but doesn't match this filing's own standalone Sep-2025 comparative column (PAT ₹3.15 Cr) — used the PDF's own same-basis standalone comparative for YoY instead of the mismatched context figure.